A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019

被引：11

作者：

Shabani, M. ^{[1
]}

Ehdaei, B. Sadegh ^{[2
]}

Fathi, F. ^{[3
]}

Dowran, R. ^{[1
]}

机构：

[1] Univ Tehran Med Sci, Sch Publ Hlth, Dept Virol, Tehran, Iran

[2] Kashan Univ Med Sci, Fac Med, Microbiol & Immunol Dept, Kashan, Iran

[3] Isfahan Univ Med Sci, Sch Med, Dept Immunol, Esfahan, Iran

来源：

NEW MICROBES AND NEW INFECTIONS | 2021年 / 42卷

关键词：

COVID-19; daclatasvir; HCV; SARS-CoV-2; sofosbuvir; HEPATITIS-C VIRUS; HCV GENOTYPE 1; PLUS SOFOSBUVIR; LIVER-TRANSPLANTATION; VIRAL-HEPATITIS; INFECTION; EPIDEMIOLOGY; RESISTANCE; INHIBITOR; EFFICACY;

D O I：

10.1016/j.nmni.2021.100895

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Sofosbuvir and daclatasvir have been used successfully since 2013 for hepatitis C treatment. It has been shown by different studies that sofosbuvir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae. Homology between hepatitis C virus RNA polymerase and severe acute respiratory syndrome coronavirus 2 has also been established. The efficacy of sofosbuvir and daclatasvir as potential choices in treating patients with coronavirus disease 2019 and their recovery can be hypothesized. (c) 2021 The Authors. Published by Elsevier Ltd.

引用

页数：4